To our knowledge, this is a rare case of semaglutide-associated SBO and concomitant AKI requiring temporary dialysis, highlighting the adverse effects of GLP-1 receptor agonists and the need for further studies to help formulate best practice guidelines. The gene discussed is GLP1R; the disease is acute kidney injury.